General Announcement::GPL receives ANDA approval for Telmisartan and Hydrochlorothiazide Tablets

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
05-Mar-2019 12:49:00
Status
New
Announcement Sub Title
GPL receives ANDA approval for Telmisartan and Hydrochlorothiazide Tablets
Announcement Reference
SG190305OTHRXFBD
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
05/03/2019 10:17:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA approval for Telmisartan and Hydrochlorothiazide Tablets USP, 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg

Attachments

PR_SGX_05032019.pdf
Total size =3255K